Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123703 | 0.93 | NCEH1 (0.40) | NCEH1MAPTRECQLKDM4EKMT2A | |
| SCHEMBL20816208 | 0.86 | PDE4A (0.36) | NCEH1MAPTRECQLKDM4EKMT2A | |
| SCHEMBL18123767 | 0.86 | NCEH1 (0.38) | NCEH1MAPTRECQLKDM4EKMT2A | |
| SCHEMBL20089224 | 0.86 | NCEH1 (0.36) | NCEH1MAPTRECQLKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL29880000 | 0.85 | NCEH1 (0.38) | NCEH1MAPTRECQLKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL29880435 | 0.85 | NCEH1 (0.35) | NCEH1MAPTRECQLKDM4EKMT2A | |
| SCHEMBL18123700 | 0.84 | NCEH1 (0.34) | NCEH1MAPTRECQLKDM4EKMT2A | |
| SCHEMBL29879818 | 0.84 | NCEH1 (0.34) | NCEH1MAPTRECQLKDM4EKMT2A | |
| SCHEMBL18123706 | 0.84 | SLC1A3 (0.35) | NCEH1MAPTRECQLKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL22772349 | 0.84 | NCEH1 (0.34) | NCEH1MAPTRECQLKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2016157052-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | NCEH1 966/4885MAPT 4840/4885RECQL 1090/4885 |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | NR0B2, NR0B1, AVPR1B | NCEH1 1245/4885MAPT 4595/4885RECQL 2634/4885 |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | NCEH1 966/4885MAPT 4840/4885RECQL 1090/4885 |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | NCEH1 966/4885MAPT 4840/4885RECQL 1090/4885 |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | NCEH1 966/4885MAPT 4840/4885RECQL 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.